Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biogen Idec Inc.    BIIB   US09062X1037

BIOGEN IDEC INC.

 (BIIB)

38
Real-time Quote. Real-time BATS US - 06/19 10:01:52 am
210.26 USD   -0.26%
1d agoDJBiogen's New Multiple Sclerosis Drug to Test Recent Stock Gains
1d ago Royalty drops hostile bid for Ireland's Elan
1d agoDJBiogen's New Multiple Sclerosis Drug to Test Recent Stock Gains
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Biogen Idec Inc. : Biogen CEO's Total Compensation Up 20% To $11.3M Last Year

03/26/2012| 02:59pm US/Eastern
Recommend:
0
    By Jon Kamp 
    Of  
 

Biogen Idec Inc.'s (BIIB) Chief Executive George Scangos saw the total value of his compensation rise 20% to $11.3 million in his first full year leading the biotechnology company, which recently was trading around an all-time high.

The shares have been helped by successful trial data for BG-12, a potential oral treatment for multiple sclerosis for which Biogen recently filed European and U.S. applications.

Scangos joined Biogen in mid-2010 and led the company through a sweeping restructuring that included cutting costs and several research and development programs.

Scangos's base salary more than doubled to $1.2 million in 2011, reflecting a full year on the job. The CEO also received a $2.7 million bonus, among other elements of his overall compensation.

Additionally, Scangos realized $4.4 million on the vesting of previously issued stock awards. Biogen disclosed details on executives' pay in a proxy filing Monday with the Securities and Exchange Commission.

Shares of the Weston, Mass., company recently traded up 3% to $124.60, near a high set Monday of $124.90, and have risen more than 13% this year.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

Recommend :
0
Partner Area
React to this article
 
Latest news on BIOGEN IDEC INC.
1d agoDJBiogen's New Multiple Sclerosis Drug to Test Recent Stock Gains
1d ago Royalty drops hostile bid for Ireland's Elan
1d agoDJBiogen's New Multiple Sclerosis Drug to Test Recent Stock Gains
6d ago Divisive Elan boss Martin faces ownership showdown
06/07DJRoyalty Pharma Raises Elan Offer to $8 Billion
06/06 Wall St. ends up in volatile trade ahead of jobs data
06/04 BIOGEN IDEC INC.: Biogen Idec 2013 Annual Shareholder Meeting Webcast
06/01DJCorrection to New Drugs for Rare Blood Cancer Story on Friday
05/31DJNew Drugs for Rare Blood Cancer Offer Opportunity
05/31DJNew Drugs for Rare Blood Cancer Present Big Opportunity
Advertisement
Chart
Duration : Period :
Biogen Idec Inc. Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Income Statement Evolution
Biogen Idec Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.